PMID- 19751468
OWN - NLM
STAT- MEDLINE
DCOM- 20100929
LR  - 20211020
IS  - 1751-7176 (Electronic)
IS  - 1524-6175 (Print)
IS  - 1524-6175 (Linking)
VI  - 11
IP  - 9
DP  - 2009 Sep
TI  - The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. 
      Therapeutic management of atherogenic dyslipidemia.
PG  - 520-7
LID - 10.1111/j.1559-4572.2009.00060.x [doi]
AB  - J Clin Hypertens (Greenwich). 2009;11:520-527. (c)2009 Wiley Periodicals, 
      Inc.Strategies for the effective management of cardiovascular risk factors in 
      patients with the metabolic syndrome (MS) or type 2 diabetes mellitus (T2DM) are 
      essential to help reduce cardiovascular morbidity and mortality. Treatment 
      strategies should be multifactorial and include the promotion of therapeutic 
      lifestyle changes, as well as pharmacologic therapies to treat individual risk 
      factors according to current guidelines. In an accompanying article, the 
      importance of atherogenic dyslipidemia as a risk factor for the development of 
      cardiovascular disease in patients with MS or T2DM was highlighted. Current 
      treatment options for managing this characteristic form of atherogenic 
      dyslipidemia are limited and tend to be only moderately effective. The focus of 
      this review is the current pharmacotherapies available for the management of 
      atherogenic dyslipidemia in patients with the MS or T2DM, highlighting the 
      rationale for combining available treatments. Novel strategies currently in 
      clinical development are also discussed.
FAU - Ginsberg, Henry N
AU  - Ginsberg HN
AD  - Department of Medicine and the Irving Institute for Clinical and Translational 
      Research, College of Physicians and Surgeons, Columbia University, New York, NY 
      10032 , USA. hng1@columbia.edu
FAU - Maccallum, Paul R
AU  - Maccallum PR
LA  - eng
GR  - R01 HL073030/HL/NHLBI NIH HHS/United States
GR  - R01 HL073030-06/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - J Clin Hypertens (Greenwich)
JT  - Journal of clinical hypertension (Greenwich, Conn.)
JID - 100888554
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Hypolipidemic Agents)
RN  - 2679MF687A (Niacin)
RN  - 53PF01Q249 (Clofibric Acid)
SB  - IM
MH  - Cardiovascular Diseases/*etiology/prevention & control
MH  - Clofibric Acid/therapeutic use
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Drug Therapy, Combination
MH  - Dyslipidemias/*etiology/prevention & control
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Hypolipidemic Agents/therapeutic use
MH  - Metabolic Syndrome/*complications
MH  - Niacin/therapeutic use
MH  - Obesity/*complications
PMC - PMC2909455
MID - NIHMS213211
EDAT- 2009/09/16 06:00
MHDA- 2010/09/30 06:00
PMCR- 2009/09/09
CRDT- 2009/09/16 06:00
PHST- 2009/09/16 06:00 [entrez]
PHST- 2009/09/16 06:00 [pubmed]
PHST- 2010/09/30 06:00 [medline]
PHST- 2009/09/09 00:00 [pmc-release]
AID - JCH60 [pii]
AID - 10.1111/j.1559-4572.2009.00060.x [doi]
PST - ppublish
SO  - J Clin Hypertens (Greenwich). 2009 Sep;11(9):520-7. doi: 
      10.1111/j.1559-4572.2009.00060.x.